Discordance of p53 status in matched primary tumours and metastases in head and neck squamous cell carcinoma patients

European Journal of Cancer Part B: Oral Oncology

Volumn 32, Issue 6, 1996, Pages 388-393

  Kropveld, A ^a   Van Mansfeld, A D M ^a   Nabben, N ^a   Hordijk, G J ^a   Slootweg, P J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Exon analysis; Head and neck cancer; Immunohistochemistry; Metastases; p53 alterations

Indexed keywords

PROTEIN P53;

ARTICLE; CLINICAL ARTICLE; DENATURING GRADIENT GEL ELECTROPHORESIS; EXON; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EXONS; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030294420     PISSN: 09641955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0964-1955(96)00030-9     Document Type: Article

References (33)

1. 1. Parkin DM, Stjernswärd J, Muir CS. Bull WHO 1984, 62, 163-182.
2. 2. Hill C, Koscielny S, Doyon F, Benhamou E. Evolution de la mortalité par cancer en France entre 1959 et 1990. Mise à jour 1986-1990. Paris, INSERM, 1993.
3. 3. Licciardello JTW, Spitz RS, Ki Hong W. Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and Lung. Int J Radiat Oncol Biol Phys 1989, 17, 467-476.
4. 4. Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989, 17, 449-456.
5. 5. Franco EL, Kowalski LP, Kanda JL. Risk factors for second cancers of the upper respiratory and digestive systems: a case control study. J Clin Epidemiol 1991, 7, 615-625.
6. 6. Macfarlane GJ, McCredie M, Pompe-Kirn V, Sharpe L, Coates M. Second cancers occurring after cancers of the mouth and pharynx: data from three population-based registries in Australia, Scotland and Slovenia. Oral Oncol, Eur J Cancer 1995, 31B, 315-318.
7. 7. Slaughter DP, Southwick HW, Smejkal W. "Field cancerization" in oral stratified squamous epithelium. Cancer 1953, 6, 963-968.
8. 8. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G. Frequent p53 mutations in head and neck cancer. Cancer Res 1992, 52, 5996-6000.
9. 9. Maestro R, Dolcetti R, Gasperatto D, et al. High frequency of p53 gene alterations associated with protein over-expression in human squamous cell carcinoma of the larynx. Oncogene 1992, 7, 1159-1166.
10. 10. Zariwala M, Schmid S, Pfalz M, Ohgaki H, Kleihues P, Schäfer R. p53 gene mutations in oropharyngeal carcinomas: a comparison of solitary and multiple primary tumours and lymph-node metastasis. Int J Cancer 1994, 56, 807-811.
11. 11. Sakai E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 1992, 52, 927-933.
12. 12. Chang Y, Lin Y, Tsai C, et al. Detection of mutations in the p53 gene in human head and neck carcinomas by single strand conformation polymorphism analysis. Cancer Lett 1992, 67, 167-174.
13. 13. Brachman DG, Graves D, Voles E, et al. Occurrence of p53 gene deletions and human papilloma virus infections in human head and neck cancer. Cancer Res 1992, 52, 4832-4836.
14. 14. Ahomadegbe JC, Barrois M, Fogel S, et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumours and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995, 10, 1217-1227.
15. 15. Chung KY, Mukhopadhyay T, Kim J, et al. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res 1993, 53, 1676-1683.
16. 16. Wright DK, Manos NN. Sample preparation from paraffin-embedded tissues. In Innes MA, Gelfand DH, Sninsky JJ, White TJ, eds. PCR Protocols. San Diego, Academic Press, 1990, 153-158.
17. 17. DiGuiseppe JA, Hruban RH, Offerhaus GJA, et al. Detection of k-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol 1994, 144, 889-895.
18. 18. Top B. A simple method to attach a universal GC-clamp to PCR fragments used for mutation analysis by DGGE. PCR Meth Appl 1992, 2, 83-85.
19. 19. Myers RM, Maniatis T, Lerman LS. Detection and localization of single base changes by denaturing gradient gel electrophoresis. Meth Enzymol 1987, 155, 501-527.
20. 20. Spiessl B. UICC, International Union Against Cancer. TNM-Atlas: Illustrated Guide to the TNM/pTNM-Classification of Malignant Tumors, 3rd Edition. New York, Springer, 1990.
21. 21. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 auto-regulatory feedback loop. Genes Dev 1993, 7, 1126-1132.
22. 22. El-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994, 54, 1169-1174.
23. 23. Xioing Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993, 366, 701-704.
24. 24. Sameshima Y, Matsuno Y, Hirohashi S, et al. Alterations of the p53 gene are common and critical events for the maintenance of the malignant phenotypes in small-cell lung carcinoma. Oncogens 1992, 7, 451-457.
25. 25. Burns JE, McFarlane R, Clark LJ, et al. Maintenance of identical p53 mutations throughout progression of squamous cell carcinomas of the tongue. Oral Oncol, Eur J Cancer 1994, 30B, 335-337.
26. 26. Peller S, Halevy A, Slutzki S, Kopilova Y, Rotter V. p53 Mutations in matched primary and metastatic human tumors. Mol Care 1995, 13, 166-172.
27. 27. Dinjens WNM, Weiden MM van der, Schroeder FH, Bosman FT, Trapman J. Frequency and characterisation of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 1994, 56, 630-633.
28. 28. Nees M, Homann N, Diascher H, et al. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumours. Cancer Res 1993, 53, 4189-4196.
29. 29. Nowell PC. The clonal evolution of tumor cell populations. Science 1976, 194, 23-28.
30. 30. Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988, 239, 487-491.
31. 31. Reichel MB, Ohgaki H, Petersen I, Kleihues P. p53 mutations in primary human lung tumors and their metastases. Mol Carc 1994, 9, 105-109.
32. 32. Boyle JO, Hakim J, Koch W, et al. The incidence of p53 mutations increase with progression of head and neck cancer. Cancer Res 1993, 53, 4477-4480.
33. 13. Koch WM, Boyle JO, Mao L, Hakim J, Hruban RH, Sidransky D. p53 gene mutations as markers of tumor spread in synchronous oral cancers. Arch Otolaryngol Head Neck Surg 1994, 120, 943-947.